<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311710</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-76U</org_study_id>
    <nct_id>NCT04311710</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types</brief_title>
  <acronym>CheckMate 76U</acronym>
  <official_title>A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab&#xD;
      applied under the skin in various tumor types&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 25, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Actual">January 14, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 Arm A: Average concentration of ipilimumab (Cavg21d)</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 Arm A: Area under the concentration in ipilimumab AUC(0-21d)</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 Arm A: Maximum observed serum concentration of ipilimumab (Cmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 Arm A: Observed concentration of ipilimumab at 21 days post dose (C21d)</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm A: Average concentration in ipilimumab (Cavg42d)</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm A: Area under the concentration in ipilimumab AUC(0-42d)</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm A: Maximum observed serum Concentration of Ipilimumab (Cmax)</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm A: Observed concentration in ipilimumab (C42d)</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm B: Average concentration of Ipilimumab at 21 days post dose (Cavg21d)</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm B: Area Under the Concentration in Ipilimumab AUC(0-21d)</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm B: Maximum observed serum Concentration in Ipilimumab (Cmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm B: Observed concentration of ipilimumab at 21 days post dose (C21d)</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Arm B: Time of maximum observed concentration in Ipilimumab (Tmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 Arm B: Average concentration of ipilimumab without rHuPH20 (Cavg21d)</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 Arm B: Area under the concentration in ipilimumab without rHuPH20 AUC(0-21d)</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 Arm B: Maximum observed serum concentration of ipilimumab without rHuPH20 (Cmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 Arm B: Observed concentration of ipilimumab without rHuPH20 at 21 days post dose (C21d)</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 Arm B: Time of maximum observed concentration in ipilimumab without rHuPH20 (Tmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AE's)</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE's leading to discontinuation</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instance of Anaphylactic occurring within 2 days of study drug administration</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instance of hypersensitivity occurring within 2 days of study drug administration</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypersensitivity occurring within 2 days of study drug administration</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infusion reactions occurring within 2 days of study drug administration</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of injection occurring within 2 days of study drug administration</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who develop anti-ipilimumab antibodies</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who develop anti-nivolumab antibodies</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who have developed neutralizing antibodies</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1 Arm A: mM, mUC, HCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metastatic Melanoma (mM), metastatic Urothelial Carcinoma (mUC), and advanced Heptocellular Carcinoma (HCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm B: mM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metastatic Melanoma (mM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm A: NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metastatic non small cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm B: RCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>advanced or metastatic renal cell carcinoma (RCC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part 1 Arm A: mM, mUC, HCC</arm_group_label>
    <arm_group_label>Part 1: Arm B: mM</arm_group_label>
    <arm_group_label>Part 2: Arm A: NSCLC</arm_group_label>
    <arm_group_label>Part 2: Arm B: RCC</arm_group_label>
    <other_name>(BMS-734016)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part 1 Arm A: mM, mUC, HCC</arm_group_label>
    <arm_group_label>Part 1: Arm B: mM</arm_group_label>
    <other_name>(BMS-936558)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENHANZE (rHuPH20)</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part 1 Arm A: mM, mUC, HCC</arm_group_label>
    <arm_group_label>Part 2: Arm A: NSCLC</arm_group_label>
    <arm_group_label>Part 2: Arm B: RCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part 2: Arm A: NSCLC</arm_group_label>
    <arm_group_label>Part 2: Arm B: RCC</arm_group_label>
    <other_name>(BMS-986298)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women must follow methods of contraception as described in the protocol&#xD;
&#xD;
        Part 1 Arms A and B: Metastatic Melanoma&#xD;
&#xD;
        - Previously untreated, histologically confirmed stage IV melanoma, as per American Joint&#xD;
        Committee on Cancer (AJCC) staging system v.8.0&#xD;
&#xD;
        Part 1 Arm A:Advanced/mUC - Participants with histologically or cytologically confirmed&#xD;
        urothelial carcinoma.&#xD;
&#xD;
        Part 1 Arm A: Advanced HCC&#xD;
&#xD;
          -  Participants with histological confirmation of Hepatocellular Cancer (HCC)&#xD;
&#xD;
        Part 2 Arm A: Metastatic NSCLC&#xD;
&#xD;
        - Participants with histologically confirmed stage IV or recurrent Non Small Cell Lung&#xD;
        Cancer (NSCLC)&#xD;
&#xD;
        Part 2 Arm B: Advanced or Metastatic RCC&#xD;
&#xD;
          -  Histological confirmation of Renal Cell Carcinoma (RCC)&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1 and for RCC (Part 2 Arm B), Karnofsky performance&#xD;
             status ≥ 70%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - History of allergy or hypersensitivity to study drug components&#xD;
&#xD;
        Part 1 Arm A: Advanced HCC&#xD;
&#xD;
          -  History of hepatic encephalopathy or evidence of portal hypertension&#xD;
&#xD;
          -  Active coinfection with hepatitis D virus infection in participants with HBV&#xD;
&#xD;
        Part 2 Arm A:Metastatic NSCLC&#xD;
&#xD;
        - Participants with known ALK translocations and EGFR mutation that are sensitive to&#xD;
        available targeted inhibitor therapy&#xD;
&#xD;
        Other inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapie</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas-U.O di Oncologia medica ed Ematologia</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ospedale le scotte-U.O.C. Immunoterapia Oncologica</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer, renal cancer, bladder cancer, skin cancer, liver cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

